CuroVax key facts
as of Oct 2026- Manufacturer of human vaccine products and immunization technologies aims to advance global public health through innovative vaccine development.
- CuroVax is valued at approximately $405.0M as of Oct 2026 (last reported valuation).
- It has raised $74.2M; the latest was Later Stage VC ($47.2M) in Dec 2025.
- Notable investors include Qiming Venture Partners, Green Pine Capital Partners, Tailong VC, Hankang Capital, Beijing Jiurui Tiancheng Technology — 18 tracked in total.
- Status: Privately Held (backing).
CuroVax's last reported valuation, Jan 2024. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch CuroVax: the Monday email on marks, rounds and moves
CuroVax funding rounds
No funding rounds for CuroVax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs CuroVax
18+CuroVax valuation
CuroVax's last reported valuation was $405 million in Jan 2024. No priced round, secondary trade or fund mark has surfaced since.
CuroVax investors
18 investors are on record for CuroVax, including Qiming Venture Partners, Green Pine Capital Partners, Tailong VC and Hankang Capital.
About CuroVax
Manufacturer of human vaccine products and immunization technologies aims to advance global public health through innovative vaccine development. The company's offerings feature end-to-end capabilities in independent R&D, large-scale mammalian cell culture, antigen purification, mRNA vaccine platforms, and full-cycle GMP manufacturing across 41000 square meters of certified production space, helping healthcare providers and governments deliver safe and effective vaccines, enabling broad immunization coverage and improved global disease prevention.
- Sector
- Healthcare
- HQ
- Changzhou, China
- Founded
- 2011
- Employees
- 303
- Website
- curovax.net/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.